Target Validation Information
TTD ID	T74952
Target Name	cAMP protein kinase type II-beta (PRKAR2B)
Type of Target	Literature-reported
Drug Potency against Target	AdcAhxArg4Lys(biotin)-PEG-OMe	Drug Info	IC50 = 1200 nM	[2]
	AdcAhxArg4Lys-PEGOMe	Drug Info	IC50 = 460 nM	[2]
	AdcAhxArg4NH(CH2)6NH2	Drug Info	IC50 = 680 nM	[2]
	AdcAhxArg6	Drug Info	IC50 = 700 nM	[2]
	AdoC(Ahx)Arg6	Drug Info	IC50 = 120 nM	[1]
	AdoC(Aoc)Arg6	Drug Info	IC50 = 240 nM	[1]
	AdoC(Aun)Arg6	Drug Info	IC50 = 330 nM	[1]
	AdoC(beta-Ala)2AlaArg6	Drug Info	IC50 = 4300 nM	[1]
	AdoC(beta-Ala)Arg6	Drug Info	IC50 = 1800 nM	[1]
	AdoC(betaAsp)2AlaArg6	Drug Info	IC50 = 11100 nM	[1]
	AdoC(Dpr)2AlaArg6	Drug Info	IC50 = 2600 nM	[1]
	AdoC(GABA)Arg6	Drug Info	IC50 = 1300 nM	[1]
	AdoCGlyArg6	Drug Info	IC50 = 4000 nM	[1]
	BALANOL	Drug Info	Ki = 4.7 nM	[3]
	Ro-4396686	Drug Info	IC50 = 9010 nM	[4]
References
REF 1	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
REF 2	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
REF 3	Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address;
REF 4	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.